REG - Scancell Hlds - Presenting at the Sachs 10th Annual Oncology Forum

Scancell HoldingsAnnouncement

16/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240516:nRSP6086Oa&default-theme=true

RNS Number : 6086O  Scancell Holdings Plc  16 May 2024

16 May 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to present at the Sachs 10th Annual Oncology Innovation Forum

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, is pleased to announce that
its Chief Financial Officer, Sath Nirmalananthan, will be presenting, and
taking part in a panel discussion, at the Sachs 10th Annual Oncology
Innovation Forum taking place on the 31(st) May 2024, at the beginning of the
ASCO meeting.

 

Sath will be participating in the "Advanced Immunotherapies Panel: Cell
Therapies & Cancer Vaccines", alongside other companies including
AstraZeneca, BTIG and Lumanity. The panel will discuss the current and future
role of cell therapies and cancer vaccines and take place from 11:40am -
12:30pm CDT.

 

Sath has also been invited to give a company presentation, taking place from
1:20pm - 1:40pm CDT at Track B, Sinclair Ballroom, where he will discuss the
ongoing Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in
combination with checkpoint inhibitors (CPIs) in advanced melanoma and early
data from the ongoing Phase 1/2 ModiFY trial with patients receiving Modi-1 as
a monotherapy in a range of hard-to-treat solid tumours, which has shown good
T cell responses, safety and tolerability.

 

Sath Nirmalananthan, Chief Financial Officer and Director of Scancell, said:
"I am pleased to be invited to participate in both the panel discussion and to
present details from our ongoing Phase 2 SCOPE trial and MofiFy study at this
esteemed Forum. The program is focused on the latest innovation in IO targets
and modalities, and I am also looking forward to highlighting the potential of
our proprietary antibody technology platform and our innovative cancer
vaccines, and to showcase the great work Scancell is making in this field."

 

If you would like to arrange a meeting at the Forum, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                                  +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFMFIIELSELI